NASHVILLE, Tenn.–(BUSINESS WIRE)–August Bioservices, an emerging leader amongst contract development and manufacturing organizations (“CDMOs”) providing drug discovery, development, and manufacturing services, today revealed its new brand identity. The new brand launch follows August Bioservices’ recent investment from Oak HC/FT and the appointment of several industry executives to its leadership team, which position the company to pursue strategic initiatives to grow the business.
Today, August Bioservices provides dynamic testing capabilities for small and large molecules as well as clinical manufacturing services for vial filling, creams and ointments. Under the company’s new leadership team and fueled by capital investment from Oak HC/FT, August Bioservices will begin two major expansion projects. The company will focus on expanding capacity and adding new injectable filling platforms to its current Nashville facility. In addition, August Bioservices is actively evaluating sites to build a new state-of-the-art testing and manufacturing facility.
These parallel initiatives will allow August Bioservices to add large-scale lyophilization and sterile fill-finish capabilities to its existing clinical and commercial manufacturing offering. Together, these projects will further complement the company’s broad range of contract services for its growing portfolio of pharmaceutical and biotechnology customers.
“We are beyond excited to continue our momentum with our new branding, which we believe is an excellent representation of the way August Bioservices views our partnerships with our customers,” said Jenn Adams, CEO of August Bioservices. “We deploy multi-dimensional, integrated capabilities, flexible and scalable capacity, and unmatched scientific and manufacturing expertise to point the way forward from clinical testing to commercial success.”
“I’d like to invite all current and prospective customers and partners to spend some time getting to know the depth and breadth of August Bioservices – our new brand, our scientific platforms and our uncompromising commitment to best-in-class quality, service, processes and results,” said Joe Mase, Executive Vice President of Operations. “If you’re looking for depth of expertise and responsiveness in a CDMO partner, August Bioservices has so much to offer.”
For more detailed information about August Bioservices, please visit www.augustbio.com
ABOUT AUGUST BIOSERVICES
August Bioservices today is a team of highly experienced scientists and professionals, providing comprehensive services to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. From dynamic testing capabilities for small and large molecules to clinical manufacturing for aseptic vial filling, creams and ointments, August Bioservices is uniquely positioned to support individual projects, or to serve as an extension of its customers’ research and development teams. August Bioservices offers several unique services to its customers, including distinctive clinical packaging operations to support ongoing clinical trials, drug stability studies and controlled storage capacity. August Bioservices is also planning to scale its manufacturing capabilities to meet clinical and commercial demand for both liquid and lyophilized filling, which will help the company support its customers’ projects from the beginning stages of clinical development through successful commercial launch.
ABOUT OAK HC/FT
Founded in 2014, Oak HC/FT is the premier venture growth-equity fund investing in Healthcare Information & Services (“HC”) and Financial Services Technology (“FT”). With $1.9 billion in assets under management, we are focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to our extensive network of industry leaders. Oak HC/FT is headquartered in Greenwich, CT, with offices in Boston and San Francisco. Follow Oak HC/FT on Twitter, LinkedIn, and Medium.